Connect with us


Drugmaker Gilead to acquire CymaBay for $4.3 billion



© Reuters. FILE PHOTO: Gilead Sciences is seen in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo

(Reuters) – Gilead Sciences (NASDAQ:) on Monday said it will acquire CymaBay Therapeutics (NASDAQ:) for $4.3 billion, to expand its portfolio of liver disease drugs.

The deal will give Gilead access to CymaBay’s lead drug candidate called seladelpar for the treatment of primary biliary cholangitis, a type of chronic inflammatory liver disease.

CymaBay had submitted a marketing application to the U.S. Food and Drug Administration (FDA) for the drug in December.

Shares of CymaBay were halted ahead of the announcement in premarket hours.

Read the full article here